Sen. Hassan Presses Big Pharma Company to Restore Access to Low-Cost Asthma Inhalers for Children
May 03, 2024
May 03, 2024
WASHINGTON, May 3 -- Sen. Maggie Hassan, D-New Hampshire, issued the following news release:
U.S. Senator Maggie Hassan (D-NH) urged GlaxoSmithKline (GSK), a major pharmaceutical company, to uphold its pledge to limit out-of-pocket prices for inhalers to $35 by restoring affordable access to Flovent, the most common inhaler used by children for asthma. It is one of the only inhalers that infants and young children can use.
At the end of 2023, GSK stopped manufacturing F . . .
U.S. Senator Maggie Hassan (D-NH) urged GlaxoSmithKline (GSK), a major pharmaceutical company, to uphold its pledge to limit out-of-pocket prices for inhalers to $35 by restoring affordable access to Flovent, the most common inhaler used by children for asthma. It is one of the only inhalers that infants and young children can use.
At the end of 2023, GSK stopped manufacturing F . . .